This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Exelixis, Inc.. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Hilary Cannon: Innovator in Cancer Treatment
Introduction
Hilary Cannon is a notable inventor based in Hitchin, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative treatments for cancer. Her work focuses on the modulation of protein kinase activity, which is crucial in cancer therapy.
Latest Patents
Hilary Cannon holds a patent for her invention titled "Crystalline Forms on N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide." This invention relates to three crystalline forms of a compound designated as Form A, Form B, and Form C. The invention provides methods for the treatment of cancer by exploiting the modulation of protein kinase activity. Additionally, it includes pharmaceutical compositions containing a crystalline form of the compound and a pharmaceutically acceptable excipient.
Career Highlights
Hilary Cannon is currently employed at Exelixis, Inc., where she continues to advance her research in cancer treatment. Her innovative approach and dedication to her work have positioned her as a key figure in her field.
Collaborations
Throughout her career, Hilary has collaborated with notable colleagues, including David Igo and Tri Tran. These partnerships have further enhanced her research and contributions to the pharmaceutical industry.
Conclusion
Hilary Cannon's work exemplifies the impact of innovation in the fight against cancer. Her patented inventions and ongoing research at Exelixis, Inc. highlight her commitment to improving patient outcomes through scientific advancements.